JERUSALEM & LONDON--(BUSINESS WIRE)--Sep. 16, 2013--
Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology
development arm, and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)
have signed a multi-project alliance agreement to research and develop
first-in-class cancer drugs that modulate DNA damage and repair response
(DDR) processes in cancer cells.
DDR plays a key role in protecting cancer cells from the damaging effect
of chemotherapy – creating an in-built antidote to the toxic effects of
the anti-tumor drug. As the cancer cells that are best able to repair
the DNA damage caused by the cancer treatments survive, they replicate,
naturally selecting for the mutation with the enhanced repair capability
– leading to recurrence and resistance to treatment.
Cancer Research UK and CRT has created a world-class hub of expertise in
DDR-related basic, translational, and clinical research that is leading
the field; building the understanding that will hopefully enable
“smarter” use of this very interesting approach in the development of
new treatment options.
Based on Cancer Research UK's extensive network of leading UK
universities, and its five cancer research institutes (Gray Institute,
Oxford; Cancer Research UK Cambridge Institute; London Research
Institute; Paterson Institute, Manchester; and the Beatson Institute,
Glasgow), this hub will provide the foundations for CRT's and Teva's
work towards developing novel therapies based on DDR-related targets for
the treatment of cancer.
“For cancer patients, it is important that we maintain the momentum of
progress that has been made in oncology in recent years," said Dr.
Michael Hayden, President, Teva Global R&D and Chief Scientific Officer.
“Cancer Research UK, CRT, and their outstanding academic partners, are a
driving force in the improved understanding of cancer and its treatment.
This research collaboration will build on our understanding of how cells
repair DNA damage, help us identify possible points of therapeutic
intervention, and lead us onto a pathway toward improve clinical
outcomes for cancer patients."
The alliance provides Teva with the opportunity to research and develop
selected and differentiated novel treatments targeting DDR processes.
With a focus on mechanisms and molecular targets related to the
emergence of therapeutic resistance in cancer cells, the partnership
also opens up the potential to expand the clinical utility and
therapeutic effectiveness of Teva’s current portfolio of oncology
chemotherapeutic agents. This approach builds on Teva’s growing focus on
personalized medicine throughout its R&D pipeline, and specifically
within its oncology portfolio.
Building on a prior well-established working relationship, the
multi-year agreement sets out the provision of new molecular targets,
selected by CRT from Cancer Research UK’s portfolio of biological
research in DDR. These targets will be validated to prove their
therapeutic importance before progressing to the early stages of drug
discovery in CRT’s Discovery Laboratories. CRT and Teva will then
jointly undertake chemical lead generation activities. Under the terms
of the agreement, CRT will receive research funding and be eligible to
receive milestone payments, and royalties on projects advancing through
Teva’s drug pipeline.
Dr Hamish Ryder, director of drug discovery at CRT’s Discovery
Laboratories, said: "Cancer Research UK scientists are carrying out
exciting research in the area of DNA damage repair. Some cancer
therapies work by targeting DNA damage response pathways in cancer
cells, and finding new ways to block repair in tumors can boost the
effectiveness of existing therapies. This exciting alliance with Teva
brings together the cutting-edge research funded by Cancer Research UK,
CRT’s expertise in progressing new drug targets and Teva’s drug research
and development capabilities in a compelling partnership."
Harpal Kumar, Cancer Research UK’s chief executive, said: “Our
scientists are leading the world in understanding the machinery that
causes and subsequently repairs damage to DNA in our cells. We believe
this machinery offers many opportunities for new treatments. Cancer
Research UK has been at the heart of research that has seen survival
from cancer double in the last forty years. By working alongside
international partners from industry to discover and develop new
targeted cancer drugs we hope to be able to accelerate this progress.
This innovative alliance provides a vital new route to turn our research
excellence into new drugs to treat cancer patients, hopefully saving
more lives, more quickly."
Notes to editors: *The alliance will span the drug discovery
process - from new target validation - proving a protein’s importance as
a therapeutic target, though to lead optimization – synthesizing
compounds for further development as potential drugs.
About Cancer Research Technology
Cancer Research Technology (CRT) is a specialist commercialization and
development company, which aims to develop new discoveries in cancer
research for the benefit of cancer patients. CRT works closely with
leading international cancer scientists and their institutes to protect
intellectual property arising from their research and to establish links
with commercial partners. CRT facilitates the discovery, development and
marketing of new cancer therapeutics, vaccines, diagnostics and enabling
technologies. CRT is a wholly owned subsidiary of Cancer Research UK,
the world's leading cancer charity dedicated to saving lives through
research. Further information about CRT can be found at www.cancertechnology.com
About Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to
saving lives through research. The charity’s pioneering work into the
prevention, diagnosis and treatment of cancer has helped save millions
of lives. Cancer Research UK receives no government funding for its
life-saving research. Every step it makes towards beating cancer relies
on every pound donated. Cancer Research UK has been at the heart of the
progress that has already seen survival rates in the UK double in the
last forty years. Cancer Research UK supports research into all aspects
of cancer through the work of over 4,000 scientists, doctors and nurses.
Together with its partners and supporters, Cancer Research UK's vision
is to bring forward the day when all cancers are cured. For further
information about Cancer Research UK's work or to find out how to
support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org.
Follow us on Twitter
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas, as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.:
C. Mannix, 215-591-8912
Tomer Amitai, 972
Ran Meir, 215-591-3033
Beck Codner, 972 (3) 926-7683
Cancer Research Technology
Emma Rigby, 020 3469 8300